This medicine is authorised for use in the European Union.


Sirturo is a tuberculosis medicine that contains the active substance bedaquiline. Tuberculosis is an infection caused by the bacterium Mycobacterium tuberculosis.

Sirturo is used in combination with other tuberculosis medicines in adults and children (aged at least 5 years and weighing at least 15 kg) with tuberculosis in the lung that is multi-drug resistant (resistant to at least isoniazid and rifampicin, the two standard tuberculosis medicines). It is given when other combinations cannot be used, either because the disease is resistant to them or because of their side effects.

Tuberculosis is rare in the EU, and Sirturo was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 26 August 2005. Further information on the orphan designationEU/3/05/314.

This EPAR was last updated on 16/05/2023

Authorisation details

Product details
Agency product number
Active substance
bedaquiline fumarate
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Tuberculosis, Multidrug-Resistant
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Conditional approvalConditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see Conditional marketing authorisation.


This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
Janssen-Cilag International NV
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Turnhoutseweg 30
B-2340 Beerse

Product information

23/02/2023 Sirturo - EMEA/H/C/002614 - II/0051

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Sirturo is indicated for use as part of an appropriate combination regimen for pulmonary multidrug resistant tuberculosis (MDR TB) in adults and adolescent patients (12 years to less than 18 years of age and weighing at least 30 kg) when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Assessment history

Related content

How useful was this page?

Add your rating
3 ratings
1 rating
1 rating